Sam Brusco, Associate Editor09.18.23
Inogen, a company offering homecare respiratory products, has completed the acquisition of Physio-Assist, further expanding its respiratory portfolio.
Physio-Assist’s Simeox is a tech-enabled airway clearance and mucus management device mainly aimed at treating bronchiectasis, where the lung’s bronchi are damaged and widened, in cystic fibrosis or chronic pulmonary obstructive disease (COPD) patients.
Simeox is primarily used in pulmonary rehab centers, as well as at home. The transaction was originally announced in July.
Physio-Assist said it will now market Simeox outside the U.S., and continue with ongoing preparations for FDA submission.
“Physio-Assist's Simeox product provides a differentiated and clinically proven innovative airway clearance technology which will add a sizable, growing, and underserved airway clearance market opportunity in support of our strategy to become a multi-portfolio global respiratory care company. Welcoming Physio-Assist to Inogen will add the Simeox airway clearance and mucus management solution to our portfolio and allow us to positively impact patients earlier in their disease journey,” Nabil Shabshab, president and CEO of Inogen told the press. “I am pleased that Inogen can now deliver a broader set of effective solutions, empowering patients to better manage their respiratory conditions in the comfort of their homes while allowing the benefits of ambulation. We are also excited about Simeox’s revenue model whereby recurring revenue will be generated by the sale of disposables in addition to the capital sales per device.”
Simeox has been cleared under CE mark in the EU and is currently being sold in Europe, Asia, and the Middle East.
Physio-Assist’s Simeox is a tech-enabled airway clearance and mucus management device mainly aimed at treating bronchiectasis, where the lung’s bronchi are damaged and widened, in cystic fibrosis or chronic pulmonary obstructive disease (COPD) patients.
Simeox is primarily used in pulmonary rehab centers, as well as at home. The transaction was originally announced in July.
Physio-Assist said it will now market Simeox outside the U.S., and continue with ongoing preparations for FDA submission.
“Physio-Assist's Simeox product provides a differentiated and clinically proven innovative airway clearance technology which will add a sizable, growing, and underserved airway clearance market opportunity in support of our strategy to become a multi-portfolio global respiratory care company. Welcoming Physio-Assist to Inogen will add the Simeox airway clearance and mucus management solution to our portfolio and allow us to positively impact patients earlier in their disease journey,” Nabil Shabshab, president and CEO of Inogen told the press. “I am pleased that Inogen can now deliver a broader set of effective solutions, empowering patients to better manage their respiratory conditions in the comfort of their homes while allowing the benefits of ambulation. We are also excited about Simeox’s revenue model whereby recurring revenue will be generated by the sale of disposables in addition to the capital sales per device.”
Simeox has been cleared under CE mark in the EU and is currently being sold in Europe, Asia, and the Middle East.